{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:12:11Z","timestamp":1787026331055,"version":"build-2736575974"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      HIV\/AIDS continues to be a serious health concern of morbidity and mortality globally, and novel HIV testing is still an important component of diagnosing\u00a0HIV\u00a0earlier and reducing the spread of HIV. The Elecsys\n                      <jats:sup>\u00ae<\/jats:sup>\n                      HIV Duo assay is a 4th generation assay that can detect both HIV-1 p24 antigen (Ag) and HIV-1\/2 antibody (Ab) in parallel and show the subresults for the Ab and Ab units.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To evaluate the clinical performance of the Elecsys\n                      <jats:sup>\u00ae<\/jats:sup>\n                      HIV Duo assay on the new cobas E 801 analyzer using a large number of clinical samples from a population in southwest China.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We collected testing results and information from all patients in a large general hospital. All eligible clinical specimens were first analyzed using the Elecsys\n                      <jats:sup>\u00ae<\/jats:sup>\n                      HIV Duo assay. The test results are given either as reactive or nonreactive as well as in the form of a cutoff index (COI). All initially reactive specimens were retested in duplicate with a 3rd-generation kit. Supplementary tests were divided into Ab confirmation tests and HIV-1 nucleic acid tests. GraphPad Prism and Python were used for plotting, and SPSS 21.0 software was used for statistical analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 186391 specimens were received, and 436 patients were confirmed to be positive for HIV. Among the 86 cases with contact history available, there were more males than females, and heterosexual transmission was the most common route of HIV infection. The Elecsys\n                      <jats:sup>\u00ae<\/jats:sup>\n                      HIV Duo assay displayed 99.94%, 99.93% and 99.98% specificity for inpatient, outpatient and physical examination patients, respectively. The median COI ratios of the false-positive group were significantly lower than those of the true-positive group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The Elecsys\n                      <jats:sup>\u00ae<\/jats:sup>\n                      HIV Duo test (Cobase801 analyzer) differentiates the detection of HIV-1 p24 Ag and HIV-1\/2 Ab with high specificity and facilitates the diagnosis of patients with early HIV infection. Therefore, the Elecsys\n                      <jats:sup>\u00ae<\/jats:sup>\n                      HIV Duo test is used for differentiation of antigen and antibody reactivity, making it suitable for routine clinical diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2022.877643","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T01:53:30Z","timestamp":1652838810000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical Application Evaluation of Elecsys\u00ae HIV Duo Assay in Southwest China"],"prefix":"10.3389","volume":"12","author":[{"given":"Mei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanmin","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1128\/CVI.00053-16","article-title":"Human Immunodeficiency Virus Diagnostic Testing: 30 Years of Evolution","volume":"23","author":"Alexander","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/bmj.39183.534919.94","article-title":"Global Health: Great Expectations","volume":"334","author":"Brown","year":"2007","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jcv.2017.04.014","article-title":"Relevance of Cutoff on a 4th Generation ELISA Performance in the False Positive Rate During HIV Diagnostic in a Low HIV Prevalence Setting","volume":"92","author":"Chac\u00f3n","year":"2017","journal-title":"J. Clin. Virol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1473-3099(12)70273-6","article-title":"Combination Implementation for HIV Prevention: Moving From Clinical Trial Evidence to Population-Level Effects","volume":"13","author":"Chang","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"S270","DOI":"10.1086\/655651","article-title":"The Detection of Acute HIV Infection","volume":"202","author":"Cohen","year":"2010","journal-title":"J. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.celrep.2019.03.097","article-title":"Comprehensive Profiling of HIV Antibody Evolution","volume":"27","author":"Eshleman","year":"2019","journal-title":"Cell Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1097\/00002030-200309050-00005","article-title":"Dynamics of HIV Viremia and Antibody Seroconversion in Plasma Donors: Implications for Diagnosis and Staging of Primary HIV Infection","volume":"17","author":"Fiebig","year":"2003","journal-title":"Aids"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/j.1537-2995.2009.02572.x","article-title":"Analysis of Sample-To-Cutoff Ratios on Chemiluminescent Immunoassays Used for Blood Donor Screening Highlights the Need for Serologic Confirmatory Testing","volume":"50","author":"Kiely","year":"2010","journal-title":"Transfusion"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/jalm\/jfab069","article-title":"Real-World Clinical Performance Evaluation of a Fourth-Generation HIV Antigen\/Antibody Differentiation Test","volume":"6","author":"Krasowski","year":"2021","journal-title":"J. Appl. Lab. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-015-0086-3","article-title":"Spectrum of False Positivity for the Fourth Generation Human Immunodeficiency Virus Diagnostic Tests","volume":"13","author":"Liu","year":"2016","journal-title":"AIDS Res. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"19605","DOI":"10.1038\/s41598-020-76549-6","article-title":"Validation of the BD FACSPresto System for the Measurement of CD4 T-Lymphocytes and Hemoglobin Concentration in HIV-Negative and HIV-Positive Subjects","volume":"10","author":"Lu","year":"2020","journal-title":"Sci. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jcv.2010.09.003","article-title":"Analytical Sensitivity of Four HIV Combined Antigen\/Antibody Assays Using the P24 WHO Standard","volume":"50","author":"Miedouge","year":"2011","journal-title":"J. Clin. Virol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jcv.2018.11.005","article-title":"A Multicentre Evaluation of the Elecsys (R) HIV Duo Assay","volume":"112","author":"Muhlbacher","year":"2019","journal-title":"J. Clin. Virol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcv.2019.04.002","article-title":"BioRad BioPlex (R) HIV Ag-Ab Assay: Incidence of False Positivity in a Low-Prevalence Population and its Effects on the Current HIV Testing Algorithm","volume":"116","author":"Parker","year":"2019","journal-title":"J. Clin. Virol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1086\/499363","article-title":"Laboratory Medicine in Africa: A Barrier to Effective Health Care","volume":"42","author":"Petti","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/inthealth\/ihy077","article-title":"Pilot Testing of an Online Training Module About Screening for Acute HIV Infection in Adult Patients Seeking Urgent Healthcare","volume":"11","author":"Rafferty","year":"2019","journal-title":"Int. Health"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02045-17","article-title":"Comparison of Detection Limits of Fourth- and Fifth-Generation Combination HIV Antigen-Antibody, P24 Antigen, and Viral Load Assays on Diverse HIV Isolates","volume":"56","author":"Stone","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"B18","volume-title":"WHO Best Practices for Injections and Related Procedures Toolkit","year":"2010"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e22776","DOI":"10.1097\/MD.0000000000022776","article-title":"Structural Equation Modeling Test of the Pre-Intentional Phase of the Health Action Process Approach (HAPA) Model on Condom Use Intention Among Senior High School Students in Tianjin, China","volume":"99","author":"Xu","year":"2020","journal-title":"Medicine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/jmv.25845","article-title":"Performance Evaluation of Elecsys HIV Duo on Cobas E 801 Using Clinical Samples in China","volume":"92","author":"Zhang","year":"2020","journal-title":"J. Med. Virol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.877643\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T01:53:33Z","timestamp":1652838813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.877643\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":20,"alternative-id":["10.3389\/fcimb.2022.877643"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.877643","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"article-number":"877643"}}